Researchers sought to determine whether daratumumab with lenalidomide and dexamethasone would improve survival in patients with newly diagnosed multiple myeloma.
Continued approval required further verification and description of clinical benefit in confirmatory trials.
Results showed an overall response rate of 84.8%.
Progression-free survival was superior with carfilzomib plus lenalidomide and dexamethasone followed by autologous stem cell transplant.
Researchers sought to determine whether combination therapy with indatuximab ravtansine would have clinical activity in patients with relapsed/refractory multiple myeloma.
Researchers interviewed multiple myeloma patients to determine what factors influence their ability to participate in shared decision-making with their clinicians.
Researchers sought to determine whether maintenance daratumumab after autologous stem cell transplant would improve PFS in patients with multiple myeloma.
Researchers sought to determine the prognostic utility of whole-body imaging in patients with relapsed/refractory multiple myeloma prior to anti-CD38 therapy.
About 81% of patients had lymphoproliferative malignancies.
Researchers sought to determine whether a triplet regimen of melflufen, dexamethasone, and bortezomib would be safe in patients with relapsed/refractory multiple myeloma.
